Nimbus Therapeutics Secures $125 Million in Funding for Clinical Programs - MedCity News

Nimbus Therapeutics, a drug developer through computational drug discovery, announced Monday that it closed $125 million in private financing.

Bain Capital Life Sciences and SV Health Investors led the funding round. The company, founded about 13 years ago, has received more than $1 billion, including from investors such as Bill Gates, Access Biotechnology and Atlas Venture, CEO Jeb Keeper said in an interview.

Nimbus, based in Cambridge, Mass., will raise the funds in several ways, including support for its ongoing clinical trials, Keeper said. Its molecule, called NDI-034858, an oral allosteric tyrosine kinase 2 (TYK2) inhibitor, is in two phase 2b clinical trials with 250 to 260 patients. One of the trials is for the treatment of psoriasis, which is a condition that causes cells to build up and create scaly and itchy dry patches. The other is for psoriatic arthritis, which is a type of inflammatory arthritis associated with psoriasis.

“The psoriasis study will actually start in the fourth quarter of this year, and we expect next year to start a phase 3 suite of psoriasis programs, so that’s one of the main uses of this funding,” Keeper said. “We will continue to run our psoriatic arthritis trial, which is due to conclude next year. We will have to see the results of that, but we are optimistic.”

Reporting refers to when a company publishes the results of a clinical trial, which can be through publication in a journal, presentation at a conference, issuing a press release, or other means.

In addition to these psoriasis and psoriatic arthritis trials, Nimbus will use the funding to initiate additional Phase 2b trials of NDI-034858 in conditions such as lupus and irritable bowel disease. The money will also support ongoing Phase 1/2 clinical trials of NDI-101150, the company’s hematopoietic progenitor kinase 1 (HBK1) inhibitor. This is being studied for use in patients with solid tumors, Keiper said.

“We need to expand this study to probably a few 100 patients in the next year,” he said. “We’ve shared a lot of preclinical data on this program, and that’s our excitement behind it. We have not yet shared clinical data. We anticipate starting to share that next year.”

The company’s extensive portfolio was one of the reasons that led SV Health Investors to fund it.

“We are proud to lead this round of funding to advance Nimbus’ exciting pipeline of clinical and preclinical candidates,” said Nikola Tarbovic, partner at SV Health Investors, in a news release. “Nimbus has had remarkable successes in discovering and developing differentiated small molecule therapies to address significant unmet medical needs, and we are excited to support their ongoing portfolio of programs.”

Other companies in the same space as Nimbus include Bristol Myers Squibb (BMS), which created a TYK2 inhibitor, and Pfizer, which has an HBK1 inhibitor. BMS announced On Friday, his drug received approval from the US Food and Drug Administration for moderate to severe plaque psoriasis. Pfizer’s drug for solid tumors is in development.

Photo: Nimbus Therapeutics

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *